

General Information

Abstracts must be submitted by **January 15, 2024** for consideration by the Program Committee for Oral or Poster presentations. Remember, abstracts are limited to avian respiratory pathogens other than Avian Influenza (Newcastle Disease Virus, infectious bronchitis virus, infectious laryngotracheitis virus, mycoplasma, etc).

Abstracts will be reviewed and approved by the Program Committee. **ABSTRACTS NOT MEETING THE CONDITIONS FOR SUBMISSION WILL BE REJECTED.** Acceptance or rejection of each abstract will be communicated to each submitter by **February 15th, 2024.** Submitters of those abstracts accepted must register for the meeting before midnight EST on March 1st, 2018. **Those not registered by that date will be automatically withdrawn.**

Conditions for Abstract Submission

- All submissions should be in Microsoft Word (or compatible) format (.doc). They should contain a title, author(s), institutional affiliation and address, and maximum of 250 word text. Example below:

Phylogenetic and Pathological Characterization of Newcastle Disease Viruses Isolated from Double-crested Cormorants

Rue, C.A.¹, Susta, L.,² Brown, C.C.,² Pasick, J.M.,³ Swafford, S.R.⁴, Wolf, P.C.,⁵ Killian, M.L.,⁶ Pedersen, J.C.,⁶ Miller, P.J.,¹ Afonso, C.L.¹.

¹Southeast Poultry Research Laboratory, Agricultural Research Service, U.S. Department of Agriculture, 934 College Station Road, Athens, GA 30605 USA; ²University of Georgia, Department of Veterinary Pathology, Athens, GA; ³CFIA-NCFAD, 1015 Arlington Street, Winnipeg, MB R3E 3ME, Canada;

⁴USDA/APHIS/Wildlife Services, Natl. Wildlife Disease & Emergency Response Prgm. 4101 LaPorte Ave, Fort Collins, CO 80521; ⁵USDA/APHIS Wildlife Services, St. Paul Downtown Airport 644 Bayfield Street, Ste. 215 Saint Paul, MN 55107; ⁶USDA, APHIS, Diagnostic Virology Laboratory National Veterinary Services Laboratory, Avian Viruses Section Laboratory 1920 Dayton Avenue Ames, IA

An outbreak of virulent Newcastle Disease Virus (NDV) in wild double-breasted cormorants (*Phalacrocorax auritus*) occurred in North America in the summer of 2008. All ten viruses isolated from cormorants were positively identified by the USDA validated real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay targeting the matrix gene. However, the USDA validated real-time RT-PCR assay targeting the fusion gene that is specific for virulent isolates only identified one of these ten isolates. Additionally, several isolates from this outbreak have been sequenced and this information used to identify genomic changes that caused the failure of the test and to revisit the evolution of NDV in cormorants. The forward primer and fusion probe were redesigned from the 2008 cormorant isolate sequence and the revised fusion gene test successfully identified all ten isolates. Phylogenetic analyses using both full fusion sequence and the partial 374 nucleotide sequence identified these isolates as genotype V with their nearest ancestor being an earlier isolate from Nevada in 2005. Histopathological analysis of this ancestral strain showed disease in the spleen and cecal tonsil consistent with that of traditional mesogenic pathotype. Intracerebral pathogenicity assays indicated that each of these isolates are velogenic with values > 0.7 but are not more virulent than reported from earlier outbreak isolates in Canada.

- **Abstract submissions**

Please send abstracts to Brian Jordan at brian89@uga.edu.

An email acknowledgment following receipt of the abstract file will be sent to the submitter of the abstract within 48hours.

INCLUDE THE SURNAME OF THE PRESENTING AUTHOR IN THE ABSTRACT FILENAME

- Authors should indicate in the email message if they prefer an oral or poster presentation.
- The authors will be notified by February 15, 2024 as to the acceptance or rejection of the abstract
- If your abstract is accepted for poster or oral presentation, you must register and pay the registration fee by March 1, 2024 or the presentation will be cancelled.
- The accepted oral papers will be for 12 minute presentations (strict time limitation) and poster papers will be a **maximum of 2.5 ft wide X 5 ft tall (80 cm wide X 152 cm tall)**.
- The abstracts will be available in electronic format for meeting participants. Authors may submit an enhanced version of their oral and poster presentations or abstracts. **The deadline for submission of material other than the 250-word abstract is April 1, 2024.**

Abstract Submissions

The deadline for abstract submission is **January 15, 2024**.

Acceptance or rejection communicated to each submitter by **February 15th, 2024**.

The deadline for registration for presenters of accepted abstracts is **March 1, 2024**.

The deadline for additional material is **April 1, 2024**.

General format

- Use 10 point Garamond font.
- Single spacing between lines and single space between sentences should be used
- Use American English spellings for such words as hemagglutinin, esophagus, anemia, etc.

Title

The title should be brief, accurate, clear, bold font and with first letter of each word in capital letters. All authors should be given; omit academic degrees, but give affiliation and address, including zip code and country.

Abstract

Keep it concise, conveying the gist when read independently. Give meaningful facts instead of generalities. Do not exceed 250 words.